Lexpos News

Following agreement between the Department of Health and Social Care, NHS England and Community Pharmacy England, the service specification for the Pharmacy First service, which is due to commence at the end of January 2024, has been published. Alongside the service specification, the clinical pathways for the seven conditions which will be included in the [...]

The post Pharmacy First service spec and pathways published appeared first on Community Pharmacy England.

Following the news about the divestment of LloydsPharmacy branches, we have been asked about our Committee’s composition. Community Pharmacy England’s Committee is made up of 24 representatives from across the community pharmacy sector, and a non-executive chair. It has been a principle of the Committee for some time, and was affirmed by pharmacy owners in [...]

The post Community Pharmacy England Committee Composition appeared first on Community Pharmacy England.

Community Pharmacy England has joined leading charities, medical and trade associations and AstraZeneca to urge the Government to take a joined up approach for improving cardiovascular disease (CVD) outcomes. The shared vision, which was launched in Parliament on 14th November 2023, sets out a collective view for improving CVD outcomes. The paper urges a holistic [...]

The post Government advised to take a joined up approach to CVD appeared first on Community Pharmacy England.

Following discussions between Community Pharmacy England and the Department of Health and Social Care (DHSC) regarding medicine pricing issues reported by pharmacy owners, the Department has today (24/11/2023) announced the following list of price concessions for November 2023. Drug Pack size Price concession Benzoyl peroxide 5% / Clindamycin 1% gel 60 £22.15 Clotrimazole 1% cream [...]

The post November 2023 Price Concessions 2nd Update appeared first on Community Pharmacy England.

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 17 Issue 4 November 2023) has been published and includes articles on: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir E-cigarette use or vaping: reminder [...]

The post MHRA Drug Safety Update: November 2023 appeared first on Community Pharmacy England.